Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial

Summary: Background: Neonatal BCG vaccination is part of routine vaccination schedules in many developing countries; vaccination at school age has not been assessed in trials in low-income and middle-income countries. Catch-up BCG vaccination of school-age children who missed neonatal BCG vaccinatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Pereira, Susan M. (Author) , Barreto, Maurício Lima (Author) , Genser, Bernd (Author) , Rodrigues, Laura C. (Author)
Format: Article (Journal)
Language:English
Published: April 2012
In: The lancet. Infectious diseases
Year: 2012, Volume: 12, Issue: 4, Pages: 300-306
ISSN:1474-4457
DOI:10.1016/S1473-3099(11)70285-7
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/S1473-3099(11)70285-7
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1473309911702857
Get full text
Author Notes:Susan M Pereira, Mauricio L Barreto, Daniel Pilger, Alvaro A Cruz, Clemax Sant'Anna, Miguel A Hijjar, Maria Y Ichihara, Andreia C Santos, Bernd Genser, Laura C Rodrigues

MARC

LEADER 00000caa a2200000 c 4500
001 1575941724
003 DE-627
005 20230427042921.0
007 cr uuu---uuuuu
008 180604s2012 xx |||||o 00| ||eng c
024 7 |a 10.1016/S1473-3099(11)70285-7  |2 doi 
035 |a (DE-627)1575941724 
035 |a (DE-576)505941724 
035 |a (DE-599)BSZ505941724 
035 |a (OCoLC)1341010513 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pereira, Susan M.  |e VerfasserIn  |0 (DE-588)1160487758  |0 (DE-627)1023722003  |0 (DE-576)505942267  |4 aut 
245 1 0 |a Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial)  |b a cluster-randomised trial  |c Susan M Pereira, Mauricio L Barreto, Daniel Pilger, Alvaro A Cruz, Clemax Sant'Anna, Miguel A Hijjar, Maria Y Ichihara, Andreia C Santos, Bernd Genser, Laura C Rodrigues 
264 1 |c April 2012 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.06.2018 
520 |a Summary: Background: Neonatal BCG vaccination is part of routine vaccination schedules in many developing countries; vaccination at school age has not been assessed in trials in low-income and middle-income countries. Catch-up BCG vaccination of school-age children who missed neonatal BCG vaccination could be indicated if it confers protection and is cost-effective. We did a cluster-randomised trial (BCG REVAC) to estimate the effectiveness (efficacy given in routine settings) of school-age vaccination. Methods: We assessed the effectiveness of BCG vaccination in school-age children (aged 7-14 years) with unknown tuberculin status who did not receive neonatal BCG vaccination (subpopulation of the BCG REVAC cluster-randomised trial), between July, 1997, and June, 2006, in Salvador, Brazil, and between January, 1999, and December, 2007, in Manaus, Brazil. 763 schools were randomly assigned into BCG vaccination group or a not-vaccinated control group. Neither allocation nor intervention was concealed. Incidence of tuberculosis was the primary outcome. Cases were identified via the Brazilian Tuberculosis Control Programme. Study staff were masked to vaccination status when identified cases were linked to the study population. We estimated cost-effectiveness in Salvador by comparison of the cost for vaccination to prevent one case of tuberculosis (censored at 9 years) with the average cost of treating one case of tuberculosis. Analysis of all included children was by intention to treat. For calculation of the incidence rate we used generalised estimating equations and correlated observations over time. Findings: We randomly assigned 20 622 children from 385 schools to the BCG vaccination group and 18 507 children from 365 schools to the control group. The crude incidence of tuberculosis was 54·9 (95% CI 45·3-66·7) per 100 000 person-years in the BCG vaccination group and 72·7 (62·8-86·8) per 100 000 person-years in the control group. The overall vaccine effectiveness of a first BCG vaccination at school age was 25% (3-43%). In Salvador, where vaccine effectiveness was 34% (8-53%), vaccination of 381 children would prevent one case of tuberculosis and was cheaper than treatment. The frequency of adverse events was very low with only one axillary lymphadenitis and one ulcer greater than 1 cm in 11 980 BCG vaccinations. Interpretation: Vaccination of school-age children without previous tuberculin testing can reduce the incidence of tuberculosis and could reduce the costs of tuberculosis control. Restriction of BCG vaccination to the first year of life is not in the best interests of the public nor of programmes for tuberculosis control. Funding: UK Department for International Development, National Health Foundation. 
700 1 |a Barreto, Maurício Lima  |e VerfasserIn  |0 (DE-588)1057432644  |0 (DE-627)795933932  |0 (DE-576)413428176  |4 aut 
700 1 |a Genser, Bernd  |e VerfasserIn  |0 (DE-588)1030401292  |0 (DE-627)735219028  |0 (DE-576)378224581  |4 aut 
700 1 |a Rodrigues, Laura C.  |e VerfasserIn  |0 (DE-588)1100081550  |0 (DE-627)858969629  |0 (DE-576)469473401  |4 aut 
773 0 8 |i Enthalten in  |t The lancet. Infectious diseases  |d New York, NY : Elsevier, 2001  |g 12(2012), 4, Seite 300-306  |h Online-Ressource  |w (DE-627)34191200X  |w (DE-600)2070985-7  |w (DE-576)121466701  |x 1474-4457  |7 nnas  |a Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial) a cluster-randomised trial 
773 1 8 |g volume:12  |g year:2012  |g number:4  |g pages:300-306  |g extent:7  |a Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial) a cluster-randomised trial 
856 4 0 |u http://dx.doi.org/10.1016/S1473-3099(11)70285-7  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1473309911702857  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180604 
993 |a Article 
994 |a 2012 
998 |g 1030401292  |a Genser, Bernd  |m 1030401292:Genser, Bernd  |d 60000  |d 65300  |e 60000PG1030401292  |e 65300PG1030401292  |k 0/60000/  |k 1/60000/65300/  |p 9 
999 |a KXP-PPN1575941724  |e 3011440255 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Susan M Pereira, Mauricio L Barreto, Daniel Pilger, Alvaro A Cruz, Clemax Sant'Anna, Miguel A Hijjar, Maria Y Ichihara, Andreia C Santos, Bernd Genser, Laura C Rodrigues"]},"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 04.06.2018"],"origin":[{"dateIssuedDisp":"April 2012","dateIssuedKey":"2012"}],"recId":"1575941724","language":["eng"],"title":[{"subtitle":"a cluster-randomised trial","title":"Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial)","title_sort":"Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial)"}],"id":{"eki":["1575941724"],"doi":["10.1016/S1473-3099(11)70285-7"]},"relHost":[{"id":{"issn":["1474-4457"],"zdb":["2070985-7"],"eki":["34191200X"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 22.09.2021"],"origin":[{"publisherPlace":"New York, NY ; London","dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisher":"Elsevier ; Lancet Publ. Group"}],"pubHistory":["1.2001 -"],"title":[{"partname":"Infectious diseases","title_sort":"lancet","title":"The lancet"}],"titleAlt":[{"title":"The lancet <London> / Infectious diseases"}],"language":["eng"],"recId":"34191200X","disp":"Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial) a cluster-randomised trialThe lancet. Infectious diseases","physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2012","text":"12(2012), 4, Seite 300-306","volume":"12","extent":"7","issue":"4","pages":"300-306"}}],"person":[{"display":"Pereira, Susan M.","given":"Susan M.","family":"Pereira","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Barreto, Maurício Lima","role":"aut","roleDisplay":"VerfasserIn","given":"Maurício Lima","family":"Barreto"},{"display":"Genser, Bernd","role":"aut","roleDisplay":"VerfasserIn","given":"Bernd","family":"Genser"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Laura C.","family":"Rodrigues","display":"Rodrigues, Laura C."}]} 
SRT |a PEREIRASUSEFFECTIVEN2012